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B cell development in the mouse occurs in the 
fetal liver before birth and shifts shortly there-
after to the bone marrow, where it continues 
throughout life (1). The production of B cells 
is a highly ordered process, mediated by several 
transcription factors that regulate expression 
of a set of lymphoid- and B lineage–specifi  c 
genes at well-defi  ned developmental stages (2). 
Thus, Ig heavy chain DHJH rearrangements oc-
cur on both chromosomes in pro–B cells, fol-
lowed by VH to DHJH rearrangement to yield 
a functional heavy chain protein in pre–B cells. 
Heavy chain protein then associates with sur-
rogate light chain components to form a pre–B 
cell receptor that signals events required for 
development to later stages, where Ig light 
chain rearranges and associates with heavy 
chain,   allowing its expression on the surface of 
a newly formed B cell (3). Although such de-
velopment from pro–B to pre–B and B cell is 
relatively well characterized (4), the very early 
B lineage stages, before CD19 expression, are 
less well understood (5–8).
Diff   erentiation from hematopoietic stem 
cells to early B lineage cells proceeds through 
a series of intermediate steps during which cells 
are thought to become progressively more re-
stricted in their developmental potential (9). 
In this model of development, hematopoietic 
stem cells produce multilineage progenitors 
(MLPs) that are capable of developing into ery-
throid, myeloid, and lymphoid lineage cells. 
Then these MLPs generate progeny popula-
tions restricted to either lymphoid (common 
lymphoid progenitor [CLP]) or erythroid/my-
eloid (common myeloid progenitor) cell lin-
eages (10, 11). CLP stage cells eventually 
generate CD19+ pro–B cells. Immediately be-
fore the CD19+ pro–B stage, cells that appear 
B lineage restricted have been identifi  ed (5, 7, 
8, 12) based on expression of CD45R/B220 
and are hereafter referred to simply as B220. 
These cells rapidly generate CD19+ pro–B cells 
in vitro and so we have referred to them as pre-
pro–B cells (5, 7, 13), a stage presumed to be in-
termediate between the CLP and CD19+ stages 
of development.
On the other hand, clear identifi  cation of these 
early CD19– stages, defi  ning the point at which 
they become committed to the Blineage (14) 
<doi> 10.1083/jem.20052444</doi><aid>20052444</aid>Lineage specifi  cation and plasticity 
in CD19− early B cell precursors
Lynn L. Rumfelt, Yan Zhou, Benjamin M. Rowley, Susan A. Shinton, 
and Richard R. Hardy
Division of Basic Sciences, Fox Chase Cancer Center, Philadelphia, PA 19111
We describe here three CD19– B cell precursor populations in mouse bone marrow identi-
fi  ed using 12-color fl  ow cytometry. Cell transfer experiments indicate lineage potentials 
consistent with multilineage progenitor (MLP), common lymphoid progenitor (CLP), and 
B lineage–restricted pre-pro–B (Fr. A), respectively. However, single cell in vitro assays reveal 
lineage plasticity: lymphoid/myeloid lineage potential for CLP and B/T lineage potential for 
Fr. A. Despite myeloid potential, recombination activating gene 2 reporter activation is fi  rst 
detected at low levels in most MLP cells, with 95% of CLPs showing 10-fold increased 
levels. Furthermore, single cell analysis shows that half of CLP and 90% of Fr. A cells 
contain heavy chain DJ rearrangements. These data, together with expression profi  les of 
lineage-specifi  c genes, demonstrate progressive acquisition of B lineage potential and 
support an asynchronous view of early B cell development, in which B lineage specifi  cation 
initiates in the MLP/CLP stage, whereas myeloid potential is not lost until the pre-pro–B 
(Fr. A) stage, and B/T lymphoid plasticity persists until the CD19+ pro–B stage. Thus, MLP, 
CLP, and Fr. A represent progressively B lineage–specifi  ed stages in development, before the 
CD19+ B lineage–committed pro–B stage.
CORRESPONDENCE
Richard R. Hardy:
rr_hardy@fccc.edu
Abbreviations used: CLP, 
  common lymphoid progenitor; 
DL1, Delta-like 1; FTOC, fetal 
thymic organ culture; LSK, 
LIN−Sca1+cKit+; MLP, multi-
lineage progenitor; SCF, stem 
cell factor.
L.L. Rumfelt’s present address is Department of Research and 
Molecular Biology, Sunnybrook & Women’s College Health 
Science Centre, Toronto, Ontario M4N 3M5, Canada.
<NOHTML>The online version of this article contains supplemental material. </NOHTML>676  CD19− B CELL PRECURSOR STAGES | Rumfelt et al.
and lose the capacity to generate alternate hematopoietic cell 
types, has been diffi   cult and remains in dispute (15–17). B cell 
developmental stages in mouse bone marrow have been subdi-
vided previously based on a diverse set of cell surface proteins, 
including B220, CD19, CD43, CD24/HSA, CD25/IL2Rα, 
CD117/cKit, and CD127/IL-7Rα (13, 18–20). Diff  erential ex-
pression of steel factor (stem cell factor [SCF]) receptor CD117/
cKit and the IL-7R CD127 has been used to distinguish MLPs 
(CD117hiCD127–) from CLPs (CD117medCD127+) among lin-
eage-negative bone marrow cells (10). Although CLPs were ini-
tially described as generating lymphoid but not myeloid cells 
(10), a recent study suggests   myeloid potential in this cell fraction 
(21). Among B220+ cells, we originally identifi  ed the Fr. A pre-
pro–B cell stage based on a distinctive low level of CD24/HSA, 
constituting  1% of bone marrow (13). However, the homoge-
neity and functional lineage restriction of cells in this “Fr. A” 
have seen reassessment over time. Thus, it became clear that the 
Fr. A “pre-pro–B” cell fraction as initially described contained 
non–B lineage cells (5, 7), including CD4+ (and Ly-6C+) den-
dritic cell precursors capable of giving rise to plasmacytoid den-
dritic cells (22, 23). More recently, using expression of the 
lymphoid-restricted gene TdT, some have suggested that most 
early B lineage precursors do not fall within the CD24low  fraction 
of B220+CD19– cells (15).
To resolve this ambiguity over the identifi  cation of the 
earliest B lineage precursor(s), we have applied 12-color fl  ow 
cytometry to purify homogenous precursor populations and 
then characterize their developmental potential. Importantly, 
our analysis incorporates multiple approaches for identifying 
early lymphoid stages, such as expression of TdT (15) and 
RAG-1/2 (17), use of reporter transgenic mice (17), lineage-
negative gating (10, 24), and separation based on key cell 
surface markers such as Ly6c (15), CD117/cKit, and CD127/
IL-7R (10). Using this type of analysis, we can easily corre-
late our results with analyses done by others (10, 15–17, 25). 
The goal of our work is to connect the B220–CLP stage (10) 
to the CD19+ pro–B stage through a clearly defi  ned B220+ 
pre-pro–B stage (Fr. A).
Our analysis revealed that B lineage specifi  cation initiates 
unexpectedly early, at the MLP/CLP stage in bone  marrow, 
and that there is greater persistence of lineage plasticity in 
B cell development than previously thought, such that 
  myeloid potential is not lost until B220 expression (Fr. A) 
and B/T lineage plasticity persists until the CD19+ pro–B 
stage (Fr. B).
RESULTS
Early CD93/AA4.1+ B lineage progenitor cell fractions 
revealed by 12-color fl  ow cytometry
To identify hematopoietic cells transiting from MLPs to the 
CD19+ pro–B stage, we adopted the approach pioneered by 
Muller-Sieburg et al. (24) and Spangrude et al. (25) using a 
mixture of lineage-specifi  c staining reagents to deplete ery-
throid, myeloid, and T lineage cells from bone marrow. To 
simultaneously analyze the potential B lineage precursors, we 
added reagents specifi  c for proteins that defi  ne stages of B cell 
development after CD19 expression, including B220, CD43, 
CD24, CD93, and IgM (13). We also included reagents rec-
ognizing CD117/cKIT and CD127/IL-7Rα, which have 
been used to identify the MLP and CLP fractions (10). Fig. 1 
shows analysis with these reagents, eliminating cell doublets/
aggregates by forward light scatter height/area gating; focus-
ing on intermediate-size cells by forward/side light scatter 
gating; eliminating dead cells, highly autofl  uorescent cells, 
and T cells by CD3/PI gating; and fi  nally eliminating cells 
expressing other non–B “lineage marker” proteins by gating 
with reagents specifi  c for monocyte/macrophage/granulo-
cyte/dendritic cells (CD11b, GR1, and Ly6c) and erythroid 
cells (Ter119). [ID]FIG1[/ID]
Further gating based on a display of CD19 versus CD24/
HSA allowed elimination of CD19+ (pro–B and later) B lin-
eage cells, focusing on CD19– cells, most of which expressed 
low levels of CD24. Based on previous fi  ndings that CD93/
AA4.1 is expressed from hematopoietic stem cells through 
the immature B cell stage (26–28), we selected CD93high cells, 
most of which expressed intermediate levels of CD43, similar 
to that found on CD93hiCD43medCD19+ pro–B cells (5). This 
cell fraction contained B220– and B220+ subsets.   Analyzing 
both subsets for expression of CD117 versus CD127 iden-
tifi  ed the following three cell populations: (a) B220– cells, 
some with high levels of CD117 and lacking CD127, others 
with intermediate levels of CD117 and bearing CD127; and 
(b) B220+ cell, most bearing CD127 and many with interme-
diate levels of CD117. Based on the similarity of the B220– 
fractions to very early multilineage precursors and common 
lymphoid progenitors described previously, we provision-
ally referred to these cells as MLPs and CLPs (10). We refer 
to the B220+ fraction as pre-pro–B “Fr. A” based on their 
expression of B220 and low-level expression of CD24. We 
excluded the infrequent and variable numbers of B220+ cells 
having undetectable levels of CD117 because such cells were 
not found in the B220– (CLP) fraction and showed only 
lower level expression of a RAG-2-GFP reporter compared 
with CLP, Fr. A, and pro–B stage cells (not depicted).
We then used a “back-gating” analysis, examining the 
distribution of cell surface proteins used in delineating these 
subsets to assess whether we might have excluded signifi  cant 
portions of cells belonging to the CD117hiCD127– and 
CD117medCD127+ cell populations, considered to identify 
the MLP and CLP stages, respectively (9, 10). Although all 
CD117medCD127+ were included in the CD93hiCD43med 
gate, this analysis revealed that only a portion of the 
CD117hiCD127– cells were CD93hiCD43med, with many 
more exhibiting a CD93medCD43hi phenotype. Most cells in 
the CD93medCD43hi population belong to the LIN– Sca1+cKit+ 
(LSK) fraction of very early hematopoietic cell precursors, 
including stem cells (Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20052444/DC1). Thus, it seems 
likely that the earliest stages of hematopoietic cell diff  erentia-
tion, such as LSK, have lower levels of CD93 (and higher lev-
els of CD43) than the MLP, CLP, and Fr. A stage cells that are 
the focus of this work. As Fig. S2 shows, most LIN–CD19– cells JEM VOL. 203, March 20, 2006  677
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expressing very high levels of a RAG-2 GFP reporter (see 
next section) fall within the CD117medCD127+ gate and 
these cells are predominantly CD43med and CD24low (i.e., 
are CLP and Fr. A as we defi  ne them). We conclude that 
  using the gates in Fig. 1 encompasses essentially all early 
B lineage precursors.
In a second gating approach with the same stained sample, 
we focused on cell surface proteins whose expression iden-
tifi  es Fr. A through Fr. C′, focusing on B220+CD43med cells, 
subdividing them on the basis of CD24 and CD19. Among 
these cells, most of those lacking CD19 have a distinctively 
low to undetectable level of CD24 (Fig. 1, right side). Fur-
thermore, in contrast to the relatively unimodal high-level 
CD93 expression found with CD19+ stage cells, there is con-
siderable heterogeneity in the CD24low fraction. Again, based 
on previous work showing that CD93– cells with this pheno-
type do not belong to the B lineage (5), we excluded CD93– 
cells and identifi  ed a set of CD93+CD117medCD127+ cells, 
corresponding to the pre-pro–B population (Fr. A) identifi  ed 
in the fi  rst gating analysis described above. We also distinguish 
Figure 1.  Identifi  cation of MLP, CLP, pre-pro–B (Fr. A), pro-B (Fr. 
B and C), and early pre–B (Fr. C′) stages using a combination of 
fl  uorescent reagents and 12-color fl  ow cytometry. The staining 
  reagents are described in Materials and methods. Two gating approaches 
are used to discriminate these stages: one for the three earliest, shown on 
the left, and another for three later stages, shown on the right. 5 × 105 
bone marrow cells were analyzed. Data shown are representative of more 
than 10 independent analyses using 6–12-wk-old BALB/c female mice.678  CD19− B CELL PRECURSOR STAGES | Rumfelt et al.
two subsets of CD43+CD19+ stage cells, with intermediate 
and high levels of CD24, respectively. Both of these fractions, 
corresponding to stages termed pro–B (Fr. B and Fr. C) and 
early pre–B (Fr. C′;  <CIT>reference 13</CIT>), express homogenous high 
levels of CD93 and are CD127+, but have variable (in B 
and C) to undetectable (in C′) levels of CD117. Table I sum-
marizes the surface markers used in identifying the CD19– 
fractions and CD19+ pro–B fractions examined in this work. [ID]TBL1[/ID]
Cell transfer analysis supports designation of CD19− cell 
fractions as MLP, CLP, and Fr. A
Next, we tested the capacity of cells in these cell fractions to 
engraft B, T, NK, and myeloid cells using a standard Ly5-
congenic competition assay (Fig. 2).[ID]FIG2[/ID] Thus, we injected Ly5.2 
sorted cells mixed with a constant amount of Ly5.1 unfrac-
tionated bone marrow i.v. into lethally irradiated Ly5.1 re-
cipient mice and examined the Ly5.1/Ly5.2 chimerism in 
diff  erent hematopoietic cell lineages 3 wk after transfer. This 
approach shows how a hematopoietic progenitor’s fate is read 
out in the context of the whole organism environment.
Fig. 2 A shows the percent of each specifi  c cell type con-
tributed by the purifi  ed precursor population in various tis-
sues, demonstrating robust multilineage reconstitution by the 
CD117hiCD127– (MLP) fraction, where we obtained large 
numbers of Ly5.2+ myeloid cells and macrophages in bone 
marrow, T lineage cells in thymus and spleen, and B cells in 
spleen. We also detect excellent engraftment of DX5+ NK 
cells. T cell reconstituting capacity at 3 wk after transfer was 
most clearly revealed by analysis of thymus engraftment, the 
primary site of T cell development. Therefore, Fig. 2 B pre-
sents the absolute numbers of myeloid, T, and B cells gener-
ated in bone marrow, thymus, and spleen, setting the values 
obtained with the MLP fraction to 1.0 and expressing the 
others relative to it. The greater numbers engrafted by MLP 
stage cells likely represent their capacity to proliferate signifi  -
cantly as precursors, before diff  erentiating into the various 
hematopoietic cell types analyzed here. Although fewer cells 
were produced with transfers of CD117medCD127+B220– (CLP) 
fraction cells, we nonetheless observed a clear lymphoid-
  restricted repopulation of T, B, and NK cells (and few mye-
loid cells). Transfer of CD117medCD127+B220+ (Fr. A) cells 
engrafted far fewer T cells (evident from analysis of thymus; 
Fig. 2 B) and few NK cells, and still generated a signifi  cant 
population of B cells, suggesting a clear delineation of 
Fr. A pre-pro–B cells. As expected, the CD19+ Fr. B subset 
produced the clearest B cell–restricted repopulation. In 
Figure 2.  B, T, NK, and myeloid engraftment from MLP stage cells, 
in contrast with predominant lymphoid repopulation using CLPs, 
and predominant B cell repopulation using Fr. A. Cell populations 
defi  ned as in Fig. 1 were isolated by cell sorting from B6.Ly5.2 mouse 
bone marrow and injected i.v. together with unfractionated bone marrow 
from B6 wild-type (Ly5.1) mice into lethally irradiated B6 mice. After 3 wk, 
recipient animals were killed and indicated tissues were analyzed by fl  ow 
cytometry for the presence of Ly5.1/Ly5.2 cells in B (B220+CD19+IgM+), 
T (CD4/C8+CD3+), NK (NK1.1/DX5+), and myeloid (CD11b/GR1+) cell pop-
ulations. (A) Percent engraftment reported is frequency of Ly5.2+ cells 
divided by total cell frequency for the indicated population. (B) Absolute 
numbers of Ly5.2+ cells of the indicated cell type were determined and 
then compared with the number obtained with MLP stage cells (defi  ned 
as 1.0 for each cell type). Error bars show standard error for analyses of 
6–10 individual recipients from four separate experiments.
Table I.  Cell surface protein expression used to defi  ne early B cell precursors in bone marrow
Cell surface protein MLP CLP Fr. A Fr. B&C
(all LIN–)
CD93/AA4.1 high high high high
CD117/cKit high medium medium low/–
CD127/IL-7Rα −+++
CD24/HSA(30F1) low low low +
CD45R/B220(6B2) −−++
CD19 −−−+
CD43(S7) medium medium medium mediumJEM VOL. 203, March 20, 2006  679
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  summary, cell transfer data support the designation of these 
stages as MLP, CLP, and Fr. A.
Bipotential B/myeloid assay reveals myeloid 
potential in CLPs
Next, we asked whether all CLP stage cells are lymphoid 
committed. Although the cell transfer analysis appeared to 
indicate such restriction, this assay suff  ers from at least two 
defi  cits: (a) lineage plasticity may be masked by failure of cells 
to migrate into inducing microenvironments for all potential 
alternate cell lineages; and (b) the seeding effi   ciency may vary 
among diff  erent cell subsets, making it diffi   cult to estimate 
the frequency and homogeneity of subsets under analysis. 
Therefore, we assessed lineage plasticity of cells in these early 
stages by a series of clonal (or near-clonal) in vitro assays. First, 
we investigated B/myeloid potential using a bipotential assay 
(29), depositing individual cells (1 cell/well) into a 96-well 
plate containing a preestablished S17 stromal cell monolayer 
and medium supplemented with SCF, Flt3 ligand, and IL-7 
(Fig. 3 A). [ID]FIG3[/ID] This combination of cytokines and stromal cells 
supports the growth and diff  erentiation of most early hema-
topoietic cells (30) and, under these conditions, both myeloid 
and B lymphoid cells can develop clonally with high effi   -
ciency. Most clones developing from MLPs were myeloid 
(CD11b+/CD19–) with occasional B lineage colonies. CLP 
stage cells generated more B lineage colonies, but we also ob-
served a signifi  cant number of myeloid colonies. In contrast, 
plates sorted with the B220+ Fr. A and the CD19+ pro–B 
Fr. B and C contained very few myeloid colonies. Thus, 
  although CLPs generated numerous   myeloid colonies, few 
were seen in plates containing sorted Fr. A cells.
One possible explanation for our detection of myeloid 
potential from CLPs is heterogeneity within the cell fraction 
we identifi  ed, with only a portion being “true” CLPs. To 
address this, we examined the expression of a RAG-2 fl  uo-
rescent reporter BAC transgene (31) in these early B lineage 
fractions. Expression of recombinase activating genes has 
been considered one of the hallmarks of lymphoid specifi  ca-
tion (17). As Fig. 4 A shows, we found that all RAG+ cells are 
CD93+.[ID]FIG4[/ID] Furthermore, using the high-level CD93 gate we 
use (see Fig. 1), essentially all MLP cells express low but de-
tectable levels of GFP and some express higher levels (Fig. 
4 B). Cells in the CLP fraction show a 10-fold higher level 
than MLP, and those in Fr. A express a yet higher level. 
  Although most cells in the CLP fraction show very high lev-
els of RAG-2–GFP, there are some cells with a lower level, 
similar to MLP, so we fractionated cells based on levels of 
RAG-2–GFP to determine whether enriching for the RAG-2/
GFP highest-expressing fraction would eliminate the mye-
loid colonies for MLP or CLP cultures. This was not the case, 
as we found many myeloid colonies with MLP fraction cells 
expressing the highest levels of RAG-2/GFP and also ob-
tained signifi  cant numbers of myeloid colonies with RAG-2/
GFP-gated CLPs (Fig. 3 B). Thus, the myeloid capacity in 
CLP stage cells detected by the bipotential culture assay does 
not refl  ect a heterogeneity in the cell population that can be 
fractionated based on RAG expression. Rather, appearance 
of surface B220 expression on CD117medCD127+ cells, rec-
ognized as Fr. A, represents a clearer indicator of the loss of 
myeloid potential as B cell development progresses.
T lineage potential in Fr. A stage cells
Having observed that CLP has myeloid potential, the ques-
tion arises whether a more clearly B/T-restricted “CLP” 
stage could be identifi  ed. To examine T lineage potential, we 
undertook fetal thymic organ culture (FTOC) using the high 
oxygen submersion modifi  cation developed by Dou et al. 
(32) that facilitates clonal generation of T cells. We compared 
the capacity of the CLP, Fr. A, and pro–B stage cells (3 cells/
well) to produce T lineage cells in alymphoid lobes isolated 
Figure 3.  Bipotential stromal cell assay reveals unexpected my-
eloid capacity in CLP stage cells that is lost upon progression to the 
B220+ (Fr. A) stage. (A) Individual cells from the indicated population 
were deposited into wells of a 96-well fl  at-bottom plate containing pre-
established S17 stromal cells in complete RPMI 1640 medium, supple-
mented with SCF, Flt3L, and IL-7. After 7–10 d, plates were examined for 
cell colonies and these were harvested and analyzed by fl  ow cytometry. 
Colonies were classifi  ed as B (CD11b–CD19+), myeloid (CD11b+CD19–), or 
other (CD11b–CD19–). No mixed colonies were observed. Representative 
data from more than four separate experiments is shown. (B) A similar 
analysis was performed with cells sorted from the bone marrow of 
  RAG-2–GFP reporter mice, selecting the GFP intermediate (+) or brightest 
(++) MLP stage cells, or the GFP-high (+++) CLP or Fr. A stage cells. 
Gated regions are marked on the GFP histograms in Fig. 4. Representative 
data from more than four separate experiments is shown.680  CD19− B CELL PRECURSOR STAGES | Rumfelt et al.
from RAG-2/common γ chain double-defi  cient  embryos 
that lack endogenous lymphoid/NK lineage development 
(Fig. 5 A). [ID]FIG5[/ID] It was striking that equal numbers of wells con-
taining early T lineage cells ( 60%) arose from both CLP and 
Fr. A. And, as would be expected, none were generated using 
CD19+ pro–B cells. These early T lineage cells, generated 
under conditions of high levels of IL-7, typically showed a 
very immature phenotype, expressing CD90 and CD25, but 
lacking CD3, CD4, or CD8. They were not stained by rea-
gents specifi  c for B lineage (CD19), myeloid lineage (CD11b 
and GR1), or NK lineage (NK1.1 and DX5) cells.
Although our FTOC data indicated a signifi  cant capacity 
for T cell production from Fr. A, comparable to the CLP 
fraction, limitations on the number of thymic lobes required 
a 3 cell/well assay to generate signifi  cant numbers of engrafted 
lobes. Therefore, we undertook a single cell assay using the 
recently described Delta-like 1 (DL1)-OP9 system (33). 
  Engagement of Notch-1 by DL1 delivers a critical signal 
specifying the T cell fate in developing hematopoietic cells 
(34, 35), and Schmitt et al. (33) found that DL1-transduced 
OP9 stromal cells could induce T cell development from 
early precursors in vitro. The OP9 cell line also supports 
  effi   cient development of B lineage cells under these culture 
conditions and thus a T/B bipotential assay is possible using 
this approach. We found that the assay works well at the single 
cell/well level and compared the capacity of CLP and Fr. A to 
produce T and B lineage cells. As shown in Fig. 5 B, similar 
to the FTOC assay, we observe effi   cient T lineage generation 
from both CLP and Fr. A, but with a bias toward B lineage 
development apparent in Fr. A (Fig. 5 B). Interestingly, in 
our analysis, T cell generation occurs at the expense of B cell 
generation, with similar numbers of total clones in both con-
trol and DL1 cultures. Thus, under conditions favorable for 
generating B cells, Fr. A can generate T cells if a Notch-1 
  signal is provided.
Ig heavy chain rearrangement initiates very early 
in B lineage development
While our RAG-2 reporter analysis (Fig. 4 B) indicated that 
RAG transcription is already activated in nearly 100% of 
MLP stage cells, it was unclear when DHJH rearrangement 
initiated because chromatin confi  guration at the heavy chain 
locus will play a key role in determining heavy chain locus 
accessibility. Therefore, we then focused on this issue. To 
determine the frequency of cells with Ig heavy chain locus 
recombination we used a single cell DNA PCR assay (7, 36, 
37). This approach uses two rounds of amplifi  cation with 
nested primers, one set that amplifi  es a germline band and 
another set that detects many of the possible DHJH rearrange-
ments, allowing us to assess the extent of heavy chain rear-
rangement at the single cell level. Importantly, this assay was 
very effi   cient, recovering signals from 80% of the cells ana-
lyzed (Table II). [ID]TBL2[/ID] The earliest fraction, MLP, showed germ-
line bands with little detectable DHJH rearrangement (<2%). 
Yet, we detected DHJH rearrangement in 48% of signal-
  positive CLP stage cells, and rearrangement increased to 88% 
of Fr. A cells (Table II, see values in parenthesis). Thus, even 
cells with extensive DJ rearrangement retain the capacity to 
develop into T cells. In comparison, CD19+ pro–B stage 
cells had extensive DHJH bands with essentially no germline 
signal, indicating that most cells had DHJH rearrangements on 
both chromosomes, consistent with a previous analysis using 
a germline-loss bulk PCR assay (13).
Quantitative analysis of expression of B, T, and myeloid-
associated genes by RT-PCR
To more completely understand the progressive restriction of 
lineage potential in each cell fraction at these developmental 
stages, we next performed quantitative analysis of gene ex-
pression using a TaqMan PCR assay for a set of genes previ-
ously used by us and others to characterize early stages in 
B  cell development, in contrast with that of myeloid and 
T lineage cells (Fig. 6). [ID]FIG6[/ID] A very clear fi  nding was the presence 
of mRNA for genes involved in Ig recombination earlier 
than conventionally expected. TdT, RAG-1, and RAG-2 
were all found at signifi  cant levels in CLP stage cells, well be-
fore surrogate light chain message (Fig. 6 A). The activation 
of these key components of the recombinase system explains 
the observation of extensive D-J rearrangement in CLP stage 
cells shown above. TdT, previously suggested as a marker for 
Figure 4.  (A) Detection of RAG-2 gene transcriptional activation 
very early in hematopoietic development. LIN– cells, gated to eliminate 
CD43– pre–B and later stage B lineage cells, were analyzed for expression 
of RAG-2–GFP and CD93. Vertical bar indicates the demarcation between 
positive and negative GFP levels. (B) Comparison of levels of RAG-2–GFP 
in early stages of B lineage development in mouse bone marrow. The level 
of green fl  uorescence detected in RAG-2–GFP transgenic– littermates is 
shown for each cell subset analyzed. Numbers on the plots show the 
mean fl  uorescence intensity for each population. Sort gates for the 
cells analyzed in B/Myeloid bipotential assays (Fig. 3 B) are indicated. 
  Representative data of three separate analyses is shown.JEM VOL. 203, March 20, 2006  681
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B lineage– (15, 38) or lymphoid-restricted precursors (16), 
is expressed at signifi  cant levels even before the CLP stage. 
MLP stage cells show  10–15% of the peak levels detected in 
CLP and Fr. A (Fig. 6, A and B). As we noted earlier (5), Ig-β 
mRNA (B29) is expressed early in the B lineage pathway, 
before detectable Ig-α mRNA (MB1), and we confi  rm this 
in our quantitative analysis.
Several transcription factors act to regulate the B lineage 
gene program (2) and several key players are shown in Fig. 6 C. 
Interestingly, mRNA for the early acting and critical E2A 
proteins E12 and E47, diagnostic of B lineage potential (39), 
are well above background in all fractions tested (Fig. 6 C), 
suggesting that the MLP fraction identifi  ed by high levels of 
CD93 and characterized by signifi  cant RAG-2–GFP expres-
sion is already being induced along the B lineage pathway. 
In contrast, two other key B lineage transcription factors, 
EBF (40, 41) and Pax-5 (42–45), showed later induction in 
the progression from CLP (B220–) to Fr. A (B220+). PU.1, 
a transcription factor regulating B/myeloid potential by acti-
vating growth factor receptors at diff  erent levels of expression 
(46), decreases from MLP to CLP, and then decreases further 
from Fr. A to Fr. B. This is consistent with a decrease in my-
eloid potential by loss of myeloid growth factor receptors and 
induction of lymphoid potential by expression of the IL-7R 
during the course of this progression.
We also surveyed expression of genes representative of 
alternative lineage fates, including T lineage, GATA3 (47) 
and Notch-1 (33, 34), and myeloid lineage, Csf1r (48) and 
C/EBPα (49). These genes showed very signifi  cant decreases 
in the progression from CLP to Fr. A to the CD19+ pro–B 
Figure 5.  Comparable T cell potential in CLP and Fr. A stage cells. 
(A) Three cells of the indicated population were deposited into wells con-
taining a fetal thymic lobe. Plates were then maintained under high oxy-
gen submersion FTOC conditions in the presence of SCF and IL-7. Wells 
were analyzed after 2 wk and evaluated for the presence of CD90/
Thy1.2+CD25+ early T lineage cells or CD19+ B lineage cells. B lineage 
cells were not effi  ciently generated under the conditions used. Data from 
fi  ve separate experiments is shown. (B) Individual CLP and Fr. A cells were 
deposited by electronic cell sorting into microplate wells containing  
DL1-OP9 or GFP-OP9 (control) stromal cells and the type of cells gener-
ated was assayed 7–10 d later. B and T lineage cells were identifi  ed as 
  described above. “Other” stands for not falling into either gate.
Table II.  Single cell heavy chain locus germline/DHJH 
rearrangement analysis
  Bone marrow fraction
Band(s) detected MLP CLP Fr. A Fr. B&C
GL 89.6 (98.4) 42.2 (51.6) 9.9 (12.0) 0.5 (0.8)
GL/DHJH 1.0 (1.1) 12.0 (14.7) 10.4 (12.6) 0.5 (0.8)
DHJH 0.5 (0.6) 27.6 (33.7) 62.0 (75.3) 62.0 (98.4)
Frequency of samples with the indicated band pattern (GL only, GL and DHJH, or DHJH 
only). 240 wells of each cell type were analyzed, one half of fi  ve separate 96-well 
plates, representing three separate sorting experiments. Value in parenthesis is 
frequency out of samples where a signal was recovered.
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stage (Fig. 6 D). In fact, the expression of these genes was re-
ciprocal to EBF and Pax-5, consistent with a progressive re-
striction to the B lineage fate as cells pass through these three 
stages. Consistent with the myeloid potential in CLPs, there 
is little change in Csf1r mRNA levels from MLP to CLP, 
whereas the level of GATA3 rises sharply in CLPs, possibly 
indicating the activation of a T lineage program that is then 
extinguished as cells progress to express B220 and then CD19 
in the absence of Notch-1 signaling. Signifi  cantly, Notch-1 
expression is sharply up-regulated at the CLP stage, declining 
thereafter, providing a mechanism for T lineage specifi  cation 
via Notch-1 signaling in CLP and Fr. A stage cells.
Determining global patterns of gene expression 
by microarray analysis
Finally, we analyzed RNA prepared from these four early B 
lineage stages from mouse bone marrow to identify sets of 
genes that were coordinately regulated as cells progressed 
down the B cell development pathway. We generated ratios 
of signal from amplifi  ed RNA to a common reference RNA 
for two samples per fraction. Genes showing a statistically 
signifi  cant diff  erence in at least one stage were identifi  ed by 
ANOVA, and the resulting set ( 1,000 genes) was analyzed 
by KMeans clustering. The results obtained were visualized 
by a “heat map” display (Fig. 7) where individual gene levels 
are coded green for low, black for intermediate, and red for 
high.[ID]FIG7[/ID] Using this approach we can identify a set of genes that 
show low-level expression in MLP and pro–B stages, but 
higher expression in CLP and Fr. A (cluster A); another that 
is low in MLP and CLP, but increasing in Fr. A and Fr. B 
and C; and yet others where high-level expression found early 
diminishes in later fractions. Importantly, we could identify 
genes present in each cluster that were consistent with the 
patterns of expression shown in Fig. 6. Thus, cluster A 
Figure 6.  Real-time quantitative RT-PCR analysis of gene expres-
sion in early B lineage fractions isolated from mouse bone marrow. 
Results show average and standard error for three separate sorted 
samples. For each gene, maximum expression observed in the four frac-
tions tested is set to 1.0. (A) B lineage–associated or –restricted genes 
are expressed from very early stages of hematopoietic development. 
(B) Gene expression in MLP stage cells compared with that in mature 
recirculating (Fr. F) B cells, showing readily detectable levels of mRNA 
for TdT and RAG-2 at this very early stage. (C) Patterns of expression of 
transcription factors indicate an ordered sequence of gene activation 
early in B cell development. (D) Genes associated with other hematopoi-
etic lineages (Csf1R, C/EBPα, myeloid; Notch-1, GATA3, and T lineage) 
show diminishing expression as cells progress from CLP to Fr. A to 
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  includes the IL-7Rα gene, consistent with the highest stain-
ing for this protein on CLP and Fr. A. Cluster B contains 
well-known B lineage–associated transcription factors 
(Pou2af1/OCAB, EBF-1, PBX-1, LEF1, IRF4, and SPI-B) 
and a large number of lymphoid/B lineage–associated genes, 
including RAG-1, Blnk, CD19, CD79a, Cd79b, and VpreB. 
Cluster C is a group of genes sharply up-regulated at the 
pro–B stage and includes ABL-1. Cluster D includes cKit and 
one of the myeloid colony-stimulating factor receptor genes. 
Cluster E contains Csf1, the myeloid growth factor receptor 
gene that we analyzed by quantitative PCR and found was 
present in CLP and down-regulated in Fr. A (the pattern 
shown here). Cluster F includes Notch1 and GATA 3, con-
sistent with the T lineage potential of Fr. A that is lost in Fr. 
B and C. In summary, the patterns of expression that we ob-
serve are consistent with our quantitative PCR determina-
tion for every gene examined that is contained in this set of 
diff  erentially expressed genes, and this analysis identifi  es a 
large number of additional genes.
DISCUSSION
Here we identify and characterize very early stages in B cell 
development in mouse bone marrow, focusing on those be-
fore CD19 expression. Fig. 8 summarizes the features of the 
cell stages we have defi  ned. [ID]FIG8[/ID] The earliest stage, MLP, gener-
ates all lineages assayed in vivo, including B, T, NK, and 
  myeloid. The next stage, identifi  ed by cell surface markers as 
CLP, gives a lymphoid-restricted repopulation in vivo but 
has the potential to generate myeloid cells in culture, while 
half of the cells already contain DHJH rearrangements. The 
third stage, Fr. A, identifi  ed by expression of B220, generates 
predominantly B cells in vivo but has the potential to pro-
duce T cells in culture, while showing an even higher fre-
quency of DHJH rearrangement than CLP. Gene expression 
profi  les are consistent with B lineage activation at the MLP 
stage, resulting in expression of a large number of B lineage–
specifi  c genes at the CLP and Fr. A stages.
T lineage potential in Fr. A was unexpected. Previously 
we showed that a fraction of B220+CD19– cells expressing 
CD43 and CD93 (“Fr. A2”) were B lineage precursors that 
failed to generate T cells in i.v. and intrathymic assays (7). 
Using the present approach, applying greater purifi  cation cri-
teria than previously, we still fi  nd predominantly B lineage 
repopulation by a “refi  ned Fr. A” using the standard Ly-5 
marked competitive repopulation assay. Although these B220+
CD19– Fr. A cells constitute only 0.05–0.1% of total bone 
marrow cells, they constitute an important decision point in 
B cell development. However, while behaving as B lineage 
precursors in some assays, their lineage plasticity is revealed in 
the HOS-FTOC and DL1-OP9 assays. One explanation for 
this behavior is their expression of Notch-1, which can be 
activated in the thymic microenvironment or by DL1 interac-
tion in culture, redirecting their lineage fate. The contrasting 
i.v. repopulation results likely indicate that Fr. A stage cells 
only ineffi   ciently home to the thymus or else rapidly progress 
to the irreversibly B lineage–committed CD19+ stage com-
pared with earlier stages like CLP or MLP.
Myeloid cell generation from the CLP fraction was also 
surprising. Our analysis shows that although these cells have 
Figure 7.  Cluster analysis reveals distinct patters for 1,000 genes 
(out of  40,000 features on the slides used) whose expression var-
ies within the four early B lineage stages analyzed in this work. 
Heat map display of expression shows relative level for each individual 
gene: green, low; black, medium; red, high. Six patterns of expression, 
  including those present at high levels early that are down-regulated (clus-
ters D and E), those up-regulated at the CLP and Fr. A stages (cluster A), 
and those up-regulated with B cell development (clusters B and C). Clus-
ter B includes many genes considered important in B cell development, 
such as RAG-1, BLNK, CD19, CD79a, CD79b, EBF, and VpreB.
Figure 8.  Diagram of early stages in B lineage development, indi-
cating extent of DHJH rearrangement, expression of key transcrip-
tion factors, expression of a RAG-2–GFP reporter transgene, extent 
of B/T/myeloid repopulating capacity, and lineage plasticity in vitro.684  CD19− B CELL PRECURSOR STAGES | Rumfelt et al.
become considerably more lymphoid specifi  ed than MLP, 
expressing higher levels of TdT and RAG message (and 
functional RAG protein, as indicated by DHJH rearrange-
ment), they nevertheless retain signifi  cant myeloid capacity 
as revealed in the B/myeloid bipotential assay. As with Fr. A, 
the i.v. repopulation assay shows a more restricted lineage 
potential, either because these cells predominantly home to 
microenvironmental niches that disfavor myeloid develop-
ment or else rapidly progress to Fr. A in vivo. We can only 
speculate that this in vitro myeloid potential was overlooked 
previously due to diff  erences in stromal culture conditions 
that favored lymphoid progression or else to diff  erences in 
sensitivity of detection of CD45R/B220 that might have in-
cluded Fr. A in the CLP population, increasing its apparent 
lymphoid restriction. Therefore, the subdivision of B220– and 
B220+ fractions of CD117medCD127+ cells is important be-
cause it reveals clear diff  erences in lineage restriction read out 
in both in vivo and in vitro. That is, in contrast with CLP, 
most Fr. A cells did not respond to myeloid-inducing signals 
in stromal cell culture. Thus, Fr. A pre-pro–B cells behave 
as a strict “common lymphoid progenitor” in terms of their 
lineage potential.
The fi  nding of B220+ CLP is reminiscent of a previous 
report from Martin et al. (50) describing a lymphoid- restricted 
“CLP2” cell type. However, in their studies, the B220+ 
CLP-like cells were reported to lack CD117, clearly not the 
case with Fr. A. Furthermore, the CLP2 cells were described 
functionally as effi   ciently homing to the thymus, which we 
do not observe; Fr. A cells injected i.v. generate far fewer 
thymocytes compared with classical (i.e., B220–) CLP stage 
cells (Fig. 2 B). The capacity of CLP2 stage cells to home to 
the thymus led Martin et al. to propose that these cells are a 
founder population for thymic T cell development. In con-
trast, we would suggest that Fr. A stage cells are an  intermediate 
between CLP and CD19+ pro–B stage cells, in a B lineage–
specifi  ed, but not yet committed, state. Recent work from 
Allman et al. (51) has identifi  ed an early thymic progenitor 
that appears distinct from CLP2. Clearly, this issue will 
  require further investigation to clarify the relationships among 
B220+CD19– subsets from bone marrow and thymus in 
terms of lineage potentials.
A very recent report by Balciunaite et al. (21) described 
the presence of a B220+CD117+CD19– hematopoietic pro-
genitor with B, T, and myeloid potential in vitro and lym-
phoid potential in vivo. Although these authors’ limiting 
dilution analysis suggests a precursor with some similarity to 
ours, their population appears more similar to the B220– CLP 
stage we report here; the expression of B220 in our experi-
ence greatly reduces myeloid potential (by 10-fold) found in 
CLPs. Furthermore, the decrease in csfR1, a gene encoding 
the receptor for colony stimulating factor 1 (a key myeloid 
growth factor), in the progression from CLP to Fr. A pro-
vides a mechanistic explanation for the diff  erence we ob-
serve. In fact, we found that B220 expression was a better 
marker for the loss of myeloid potential than induction of a 
RAG-2–GFP reporter, sounding a cautionary note on the 
use of RAG reporters for identifying “early lymphoid 
  progenitors” (17).
Both CLP and Fr. A stage cells generated T lineage cells 
in vitro, revealing T lineage potential, but this does not nec-
essarily mean that either are normal intermediates in a devel-
opmental pathway from hematopoietic stem cells to T cells. 
Although the existence of T cell lines or thymocytes with 
Ig DHJH rearrangement have been reported (52), there are no 
T lineage precursors among triple negative (CD3–4–8–) thy-
mocytes with a surface phenotype corresponding to bone 
marrow CLP (51), and we detect no cells corresponding to 
Fr. A in the thymus (not depicted). Our results seem most con-
sistent with a type of developmental model where B lineage 
“specifi  cation” precedes B lineage commitment in bone mar-
row (53–55). In this model, B lineage genes are induced and 
non–B lineage genes are repressed in progressive stages of 
hematopoietic development, mediated by a hierarchy of 
transcription factors, resulting in a B lineage–specifi  ed stage, 
coincident with DHJH rearrangement and the high-level ex-
pression of a set of early B lineage genes, such as Igα/β, λ5/
VpreB, and RAG-1/2. However, absolute irreversible lin-
eage commitment occurs at a later stage, coincident with high-
        level expression of functional Pax-5 (42, 43).
In fact, it appears that B lineage specifi  cation  initiates 
even before the CLP stage, as MLP cells express some lym-
phoid/B lineage genes, including TdT, RAG-2, and Ig-β. 
We also note that most MLP stage cells show activation of a 
RAG reporter transgene, similar to the previously described 
CD117hi early lymphoid progenitors fraction that lacks 
CD127 (17). Nevertheless, we found a robust myeloid lin-
eage engraftment with MLP, suggesting that RAG-2 gene 
transcriptional activation, along with a signifi  cant component 
of the B lineage program, initiates in a cell fraction that main-
tains considerable myeloid potential as revealed using the cell 
engraftment competition assay.
Finally, our microarray analysis illustrates the progressive 
nature of B cell development. We identify clusters of genes 
with expression shared between MLP and CLP, between 
CLP and Fr. A, and between Fr. A and CD19+ pro–B stage 
cells. Continuing examination of the members of these clus-
ters will help to elucidate more fully the gene program result-
ing in progressive restriction to B lineage development, along 
with the key microenvironmental interactions that foster 
this process.
MATERIALS AND METHODS
Animals. 6–12-wk-old BALB/c (ICR) female mice, bred in our animal 
  facility, were used in most experiments. For the i.v. competition cell transfer 
assay, B6.Ly5.2 female mice were obtained from the National Cancer 
  Institute. RAG-2–GFP BAC transgenic mice were obtained from 
M.   Nussenzweig (Rockefeller University, New York, NY) and bred in our 
animal facility. RAG-2/common γ chain double-defi  cient  (RAG2°γC°)   
a-lymphoid animals, originally described by Colucci et al. (56), were 
  obtained from D. Wiest at our institute, and timed matings for generating 
fetal thymic lobes were performed in our animal facility. C57BL/6 mice 
were obtained from our animal facility production colony. All experiments 
with mice were conducted under an approved animal protocol.JEM VOL. 203, March 20, 2006  685
ARTICLE
i.v. competitive repopulation assay. The selected population was sorted 
from B6.Ly5.2 bone marrow and the yield derived from two bone marrow 
equivalents was transferred i.v. per recipient, typically 5–10 × 103 for 
CD19– fractions and 5–10 × 104 for CD19+ cells, together with 105 unfrac-
tionated Ly5.1 (recipient type) bone marrow. 2-mo-old C57/B6 female re-
cipient mice were lethally irradiated (9 Gy) 1 d before transfer and provided 
neomycin polymixin B antibiotic in water. Animals were analyzed 3 wk 
  after transfer, using antibodies specifi  c for Ly5.1 and Ly5.2 in addition to 
  reagents specifi  c for T, B, NK, and myeloid cells (CD3, CD4, and CD8 for 
T cells; B220, CD19, and IgM for B cells; NK1.1 and DX5 for NK cells; 
and CD11b and GR-1 for myeloid cells/granulocytes).
Myeloid/B cell bipotential stromal cell cultures. S17 stromal cells 
were grown in a 37°C humidifi  ed, 10% CO2 gassed incubator in 5% FBS/
RPMI 1640 medium (supplemented with 1× glutamine, 10 mM Hepes, 
5 × 10−5 M 2-ME, and 0.5 mg/ml gentamicin). Cells were passaged into 
96-well plates in the same medium and allowed to reach confl  uence 3–5 d 
before use. Immediately before cloning, medium was replaced with fresh 
medium containing cytokines (10 ng/ml SCF, 10 ng/ml Flt3L, and 100 U/
ml IL-7; R&D Systems). Individual cells of the selected population were 
sorted using the single cell deposition unit of a FACSVantage/DiVa fl  ow 
cytometer and then returned to the incubator. 7–10 d later wells were exam-
ined for colonies using an inverted microscope. Positive wells were har-
vested by pipetting, and then cells were stained with antibody to CD19 and 
CD11b and analyzed by fl  ow cytometry.
T cell potential assays: high-oxygen tension FTOCs and DL1-OP9. 
The modifi  ed FTOC culture under high oxygen tension was performed as 
described previously (32, 57), except that fetal thymic lobes from RAG2°γc° 
embryos were used. Three cells of selected population were sorted per well 
using the automated cell deposition unit. Cells were analyzed after 14 d by 
fl  ow cytometry, staining for CD19, CD90/Thy-1, CD25/IL-2Rα, DX5, 
CD11b, and CD11c. Early T lineage cells were recognized as CD90+CD25+ 
cells, lacking other markers tested. Alternately, individual cells selected by 
sorting were deposited into microplate wells containing preestablished stro-
mal cells, either DL1-transduced OP9 or GFP-OP9 (33). Cultures were 
performed essentially as described previously (33) and analyzed for genera-
tion of T or B cells using the staining procedure described above at 7–10 d.
Flow cytometry and monoclonal antibodies. Sorting was performed 
using a BD Biosciences FACSVantageSE/DiVa, equipped with three laser 
excitation lines (407, 488, and 600 nm) for 12-color detection. Early B lin-
eage precursors were isolated using the following staining combination: FL-
Ter119, FL–anti-Ly6c, PE-anti–IL-7Rα (SB/199), PI detected in TR-PE 
channel, Cy5PE–anti-CD3 (500A-A2), Cy55PE-CD93 (AA4.1), Cy7PE-
CD43 (S7), Alexa 594–anti-CD24/HSA (30F1), APC-CD117/cKit (2B8), 
Cy55APC–anti-CD19 (1D3), Cy7APC–anti-CD11b/Mac-1(M1/70), 
  Cy7APC-GR1, CasBlue–anti-IgM (331.12), and Bi–anti-CD45R/B220
(RA3-        6B2). Biotin reagent was revealed by second-step incubation with 
QDot605-streptavidin. Analysis was performed using either this fl  ow cy-
tometer or a BD Biosciences LSR-II with three lasers (407, 488, and 630 nm) 
equipped for 10-color detection. All reagents were made in our laboratory, 
except for QDot605-streptavidin, which was purchased from Quantum 
Dot Corporation, and DX5 from BD Biosciences. Cells from RAG-2–
GFP reporter mice were analyzed by detecting GFP in the FL channel, 
using the staining combination described above, except that Ter119 and anti-
Ly6c antibody were labeled with Cy5PE.
Single cell heavy chain recombination assay. Analysis was performed 
using a modifi  cation of procedures described previously (7, 36, 37). Cells 
were sorted directly into 96-well plates (Applied Biosystems) containing 
20 μL/well lysis buff  er (1× PCR buff  er [Applied Biosystems] with 2.5 mM 
MgCl2, 9.2 μg/ml tRNA [Sigma-Aldrich], and 100 μg/ml gelatin). Plates 
were stored at −80°C and then just before PCR, plates were thawed, treated 
with 0.5 mg/ml proteinase K for 1 h at 55°C, and then heated for 10 min at 
95°C. After digestion, a two-round nested PCR was used to detect a germ-
line DNA segment (lost upon heavy chain rearrangement) and potential 
DHJH rearrangements. The PCR program was 95°C for 1 min, 63°C for 
1 min, and 72°C for 1.5 min for 30 cycles, with a 10-min end extension at 
72°C. For round 1: GL5-1, C  C  C  G  G  A  C  A  G  A  G  C  A  G  G  C  A  G  G  T  G  G  ; DH5-1, 
A  C  A  A  G  C  T  T  C  A  A  A  G  C  A  C  A  A  T  G  C  C  T  G  G  C  T  ; and DH3-1, A G  G  C  T  C  T  G-
A  G  A  T  C  C  C  T  A  G  A  C  A  G  . For round 2, the following two separate reactions 
were performed: for germline GL5-2, G  A  G  T  T  G  A  C  T  G  A  G  A  G  G  A  C  A  G  , 
and GL3-2, C  G  A  A  G  T  A  C  C  A  G  T  A  G  C  A  C  ; and for DHJH rearrangements 
DH5-2, A  C  G  T  C  G  A  C  T  T  T  T  (G/C)T  C  A  A  G  G  G  A  T  C  T  A  C  T  A  C  T  G  T  , and 
DH3-2, G  G  G  T  C  T  A  G  A  C  T  C  T  C  A  G  C  C  G  G  C  T  C  C  C  T  C  A  G  G  G  . In the fi  rst 
round, PCR amplifi  cation was performed with the contents of each well in 
a total volume of 50 μl containing 0.2 μM dNTPs, 1 μl BD Advantage 
cDNA polymerase mix, 1× BD Advantage PCR buff  er, 0.5 mg/ml BSA, 
and 0.4 μM of each primer. In the second round, 1 μl of each fi  rst round 
product was added to a 50-μl reaction volume using the same conditions 
described above, except that second round primers (GL-5-2/GL-3-2 or DH-
5-2/DH-3-2) were used at 2 μM. Products were visualized on 1.5% agarose 
gels stained with ethidium bromide. The validity of these PCR products was 
verifi  ed by sequence analysis.
Quantitative RT-PCR assay. Total RNA was prepared by sorting cells 
into Solution D lysis/denaturing solution, followed by acid-phenol extrac-
tion and isopropanol precipitation, as described previously (5). cDNA was 
synthesized by adding 1 μl oligo-(dT)12–18 primer (0.5 μg/μL; Invitrogen) 
to 20 μl total RNA, heating at 70°C for 10 min, cooling on ice for 2 min, 
adding 8 μl 5× fi  rst-strand buff  er (Invitrogen), 4 μl 0.1 M DTT (Invitro-
gen), 4 μl dNTPs (each dNTP at 10 mM; Promega), 1 μl random hexamer 
primers (20 U/ml; GE Healthcare), 2 μl RNAsin (40 U/ml; Promega), and 
2 μl Superscript II (200 U/ml; Invitrogen), and then incubating at 42°C for 
2 h. Gene expression was quantitated by real-time PCR. Analyses were per-
formed in triplicate in 25-μl volumes using an ABI7500 thermal cycler. For 
each tube, 12.5 μl ABI TaqMan 2× Mastermix (polymerase and dNTPs), 
1.25 μl probe mix (ABI), 9.25 μl DEPC-H20, and 2 μl template (typically 
diluted 1:3 from cDNA synthesis volume) were added. ABI software was 
used to quantify/calculate Ct values and determine relative gene expression 
levels, standardizing using β-actin values. All quantitative PCR ABI assay 
IDs and sequences for custom-designed sets are available upon request.
RNA extraction from sorted cells, RNA amplifi  cation, and labeling 
for microarray. Cells were sorted directly into RNA lysis buff  er (6 M gua-
nidine thiocyanate, 0.67% Na N-lauroylsarcosine, 33 mM sodium citrate, 
and 133 mM 2-mercaptoethanol), and total RNA was extracted using the 
acid phenol method as described previously (5). Integrity and quantity of to-
tal RNA samples were analyzed using a 2100 Bioanalyzer (Agilent Technol-
ogies). 40 ng total RNA was used for RNA amplifi  cation. RNA amplifi  cation 
was performed using the Ovation Aminoallyl RNA Amplifi  cation and La-
beling System (NuGEN Technologies, Inc.) in accordance with the manu-
facturer’s protocols. 2 μg amplifi  ed cDNA was used for dye-coupling with 
Alexa Fluor 555 and Alexa Fluor 647 (Invitrogen). Quantifi  cation of the fl  u-
orescent-labeled probes was performed using a NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies). 50 pmol of fl  uorescent-labeled 
cDNA ( 1.5 μg amplifi  ed cDNA) of each probe (experimental sample and 
reference) was loaded per slide. For use as a reference, total RNA from six 
cell lines (R1, RS2, J558, EL4, DN3, and P388d) was prepared using TriRe-
agent (Molecular Research Center, Inc.) and 30 μg (5 μg from each cell line) 
was reverse transcribed at 42°C for 2 h in a total volume of 20 μl that in-
cluded 1 μl Superscript II reverse transcriptase (200 U/μl; Invitrogen), 1 μl 
rRNAsin RNAase inhibitor (40 U/μl; Promega), and 2 μl of a mixture of 
dNTPs (5 mM each of dGTP, dATP, and dCTP; 2 mM of dTTP; and 3 mM 
of aminoallyl dUTP). RNA was hydrolyzed by the addition of 10 μl 1 M 
NaOH and incubation at 70°C for 10 min. 10 μl of 1 M HCl was then added 
to neutralize the sample, and cDNA was precipitated overnight by the addi-
tion of 4 μl of 3 M sodium acetate, pH 4.5, 1 μl glycogen (20 μg/μl), and 
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70% ethanol, and dissolved in 9 μl coupling buff  er, followed by the same 
dye-coupling procedure described above for amplifi  ed cDNA.
Microarray analysis. Two samples were analyzed from each fraction 
sorted from separate pools of mouse bone marrow cells. RNA prepared 
from each sample was amplifi  ed, used for probe generation, and hybridized 
with a common reference RNA. Amplifi  ed RNA was labeled with both 
Alexa Flour 555 and Alexa Flour 647 and hybridized with the comple-
mentary labeled reference RNA (dye-fl  ip replicates). Whole mouse genome 
44K oligo microarray kits (Agilent Technologies) were used for hybridiza-
tion. The hybridization and SSPE washing and drying procedures were all 
performed according to the manufacturer’s recommendations. The slides 
were then scanned using an Agilent BA DNA Microarray Scanner. Data 
from scans were normalized using Agilent feature extraction software and 
then subject to statistical analysis using GeneSight software (BioDiscovery). 
  Results were determined as ratios of experimental sample to reference, and 
dye-fl  ip replicates were combined. The resulting data, two ratios for each 
gene from all four samples, were analyzed by ANOVA, selecting genes dif-
ferentially expressed reproducibly in at least one stage with a p-value cutoff   
of <0.005. This set of  1,000 genes was then analyzed by KMeans cluster-
ing using a distance measure based on the Pearson correlation and assuming 
six clusters.
Online supplemental material. Fig. S1 is a fl  ow cytometry analysis show-
ing the relationship between CD43 and CD93 expression with B cell devel-
opment, comparing very early precursors (LSK) with CLP and Fr. A. Fig. S2 is 
a fl  ow cytometry analysis showing the expression of a RAG-2–GFP reporter 
BAC transgene in early stages of B cell development. The microarray data used 
to generate the cluster analysis shown in Fig. 7 is also available. The online 
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20052444/DC1. The microarray data is available from ArrayExpress, 
European Bioinformatics Institute (http: www.ebi.ac.uk/arrayexpress), as 
accession no. E-MEXP-559.
We thank J. Oesterling for technical assistance with fl  ow cytometry. We appreciate 
the advice and help of Y.-S. Li with the microarray analysis. The RAG-2–GFP 
BAC transgenic reporter mice were a kind gift of M. Nussenzweig (Rockefeller 
University). We thank J.C. Zúñiga-Pfl  ücker (University of Toronto) for OP9 stromal 
cells expressing DL1. We acknowledge the help of Y. Katsura and H. Kawamoto 
(Kyoto University) for sharing a detailed protocol for the HOS-FTOC assay. We thank 
P. Kincade (Oklahoma Medical Research Foundation) for providing hybridoma-
secreting antibodies to CD117 and CD127. We appreciate helpful comments and 
suggestions on the manuscript from K. Hayakawa, K. Campbell, D. Kappes, and 
D. Wiest, all at our institute.
This work was supported by grants from the National Institutes of Health (NIH) 
to R.R. Hardy (AI26782 and AI40946). L.L. Rumfelt and B.M. Rowley were supported 
by NIH training grant AI07492.
The authors have no confl  icting fi  nancial interests.
Submitted: 7 December 2005
Accepted: 1 February 2006
R  E  F  E  R  E  N  C  E  S 
  1. Hardy, R.R. 2003. B-lymphocyte development and biology. In 
Fundamental Immunology. W.E. Paul, editor. Lippincott Williams 
& Wilkins, Philadelphia. 159–194. 
 2. Busslinger, M. 2004. Transcriptional control of early B cell develop-
ment. Annu. Rev. Immunol. 22:55–79.
  3.  Melchers, F., D. Haasner, U. Grawunder, C. Kalberer, H. Karasuyama, 
T. Winkler, and A.G. Rolink. 1994. Roles of IgH and L chains in the 
development of cells of the B lymphocyte lineage. Annu. Rev. Immunol. 
12:209–225.
 4. Hardy, R.R., and K. Hayakawa. 2001. B cell development pathways. 
Annu. Rev. Immunol. 19:595–621.
 5. Li, Y.S., R. Wasserman, K. Hayakawa, and R.R. Hardy. 1996. 
Identifi  cation of the earliest B lineage stage in mouse bone marrow. 
Immunity. 5:527–535.
 6. Rolink, A., E. ten Boekel, F. Melchers, D.T. Fearon, I. Krop, and 
J. Andersson. 1996. A subpopulation of B220+ cells in murine bone 
marrow does not express CD19 and contains natural killer cell progen-
itors. J. Exp. Med. 183:187–194.
 7. Allman, D., J. Li, and R.R. Hardy. 1999. Commitment to the B 
lymphoid lineage occurs before DH-JH recombination. J. Exp. Med. 
189:735–740.
 8. Ogawa, M., E. ten Boekel, and F. Melchers. 2000. Identifi  cation of 
CD19(−)B220(+)c-Kit(+)Flt3/Flk-2(+) cells as early B lymphoid 
precursors before pre-B-I cells in juvenile mouse bone marrow. Int. 
Immunol. 12:313–324.
 9. Kondo, M., A.J. Wagers, M.G. Manz, S.S. Prohaska, D.C. Scherer, 
G.F. Beilhack, J.A. Shizuru, and I.L. Weissman. 2003. Biology of 
  hematopoietic stem cells and progenitors: implications for clinical 
  application. Annu. Rev. Immunol. 21:759–806.
10.  Kondo, M., I.L. Weissman, and K. Akashi. 1997. Identifi  cation of clo-
nogenic common lymphoid progenitors in mouse bone marrow. Cell. 
91:661–672.
11.  Akashi, K., D. Traver, T. Miyamoto, and I.L. Weissman. 2000. A clo-
nogenic common myeloid progenitor that gives rise to all myeloid line-
ages. Nature. 404:193–197.
12. Martensson, I.L., F. Melchers, and T.H. Winkler. 1997. A transgenic 
marker for mouse B lymphoid precursors. J. Exp. Med. 185:653–661.
13. Hardy, R.R., C.E. Carmack, S.A. Shinton, J.D. Kemp, and K. 
Hayakawa. 1991. Resolution and characterization of pro–B and 
pre-pro–B cell stages in normal mouse bone marrow. J. Exp. Med. 
173:1213–1225.
14. Hardy, R.R. 2003. B-cell commitment: deciding on the players. Curr. 
Opin. Immunol. 15:158–165.
15. Tudor, K.S., K.J. Payne, Y. Yamashita, and P.W. Kincade. 2000. 
Functional assessment of precursors from murine bone marrow sug-
gests a sequence of early B lineage diff  erentiation events. Immunity. 12:
335–345.
16. Medina, K.L., K.P. Garrett, L.F. Thompson, M.I. Rossi, K.J. Payne, 
and P.W. Kincade. 2001. Identifi  cation of very early lymphoid precur-
sors in bone marrow and their regulation by estrogen. Nat. Immunol. 
2:718–724.
17. Igarashi, H., S.C. Gregory, T. Yokota, N. Sakaguchi, and P.W. 
Kincade. 2002. Transcription from the RAG1 locus marks the earliest 
lymphocyte progenitors in bone marrow. Immunity. 17:117–130.
18.  Rolink, A., and F. Melchers. 1993. B lymphopoiesis in the mouse. Adv. 
Immunol. 53:123–156.
19. Rolink, A., U. Grawunder, T.H. Winkler, H. Karasuyama, and F. 
Melchers. 1994. IL-2 receptor alpha chain (CD25, TAC) expression defi  nes 
a crucial stage in pre-B cell development. Int. Immunol. 6:1257–1264.
20. Chen, J., A. Ma, F. Young, and F.W. Alt. 1994. IL-2 receptor   alpha 
chain expression during early B lymphocyte diff  erentiation. Int. Immunol. 
6:1265–1268.
21.  Balciunaite, G., R. Ceredig, S. Massa, and A.G. Rolink. 2005. A B220+ 
CD117+ CD19− hematopoietic progenitor with potent lymphoid and 
myeloid developmental potential. Eur. J. Immunol. 35:2019–2030.
22. Miller, J.P., D. Izon, W. DeMuth, R. Gerstein, A. Bhandoola, and D. 
Allman. 2002. The earliest step in B lineage diff  erentiation from com-
mon lymphoid progenitors is critically dependent upon interleukin 7. 
J. Exp. Med. 196:705–711.
23. Nakano, H., M. Yanagita, and M.D. Gunn. 2001. CD11c+ B220+ 
Gr-1+ cells in mouse lymph nodes and spleen display characteristics of 
plasmacytoid dendritic cells. J. Exp. Med. 194:1171–1178.
24. Muller-Sieburg, C.E., C.A. Whitlock, and I.L. Weissman. 1986. 
Isolation of two early B lymphocyte progenitors from mouse marrow: 
a committed pre-pre-B cell and a clonogenic Thy-1-lo hematopoietic 
stem cell. Cell. 44:653–662.
25.  Spangrude, G.J., S. Heimfeld, and I.L. Weissman. 1988. Purifi  cation and 
characterization of mouse hematopoietic stem cells. Science. 241:58–62.
26.  McKearn, J.P., C. Baum, and J.M. Davie. 1984. Cell surface antigens ex-
pressed by subsets of pre-B cells and B cells. J. Immunol. 132:332–339.
27.  McKearn, J.P., J. McCubrey, and B. Fagg. 1985. Enrichment of hema-
topoietic precursor cells and cloning of multipotential B-lymphocyte 
precursors. Proc. Natl. Acad. Sci. USA. 82:7414–7418.JEM VOL. 203, March 20, 2006  687
ARTICLE
28. Jordan, C.T., J.P. McKearn, and I.R. Lemischka. 1990. Cellular 
and developmental properties of fetal hematopoietic stem cells. Cell. 
61:953–963.
29.  Cumano, A., C.J. Paige, N.N. Iscove, and G. Brady. 1992. Bipotential 
precursors of B cells and macrophages in murine fetal liver. Nature. 
356:612–615.
30. Borge, O.J., J. Adolfsson, and A.M. Jacobsen. 1999. Lymphoid-
  restricted development from multipotent candidate murine stem cells: 
distinct and complimentary functions of the c-kit and fl  t3-ligands. Blood. 
94:3781–3790.
31. Yu, W., Z. Misulovin, H. Suh, R.R. Hardy, M. Jankovic, N. 
Yannoutsos, and M.C. Nussenzweig. 1999. Coordinate regulation of 
RAG1 and RAG2 by cell type-specifi  c DNA elements 5′ of RAG 2. 
Science. 285:1080–1084.
32. Dou, Y.M., Y. Watanabe, Y. Aiba, K. Wada, and Y. Katsura. 1994. 
A novel culture system for induction of T cell development: modifi  ca-
tion of fetal thymus organ culture. Thymus. 23:195–207.
33. Schmitt, T.M., M. Ciofani, H.T. Petrie, and J.C. Zuniga-Pfl  ucker. 
2004. Maintenance of T cell specifi  cation and diff  erentiation requires re-
current notch receptor–ligand interactions. J. Exp. Med. 200:469–479.
34. Radtke, F., A. Wilson, G. Stark, M. Bauer, J. van Meerwijk, H.R. 
MacDonald, and M. Aguet. 1999. Defi  cient T cell fate specifi  cation in 
mice with an induced inactivation of Notch 1. Immunity. 10:547–558.
35. Pui, J.C., D. Allman, L. Xu, S. DeRocco, F.G. Karnell, S. Bakkour, 
J.Y. Lee, T. Kadesch, R.R. Hardy, J.C. Aster, and W.S. Pear. 1999. 
Notch1 expression in early lymphopoiesis infl  uences B versus T lineage 
determination. Immunity. 11:299–308.
36. Ehlich, A., V. Martin, W. Muller, and K. Rajewsky. 1994. Analysis of 
the B-cell progenitor compartment at the level of single cells. Curr. Biol. 
4:573–583.
37. Borghesi, L., and R.M. Gerstein. 2004. Developmental separation of 
V(D)J recombinase expression and initiation of IgH recombination in B 
lineage progenitors in vivo. J. Exp. Med. 199:483–489.
38. Kouro, T., K.L. Medina, K. Oritani, and P.W. Kincade. 2001. 
Characteristics of early murine B-lymphocyte precursors and their direct 
sensitivity to negative regulators. Blood. 97:2708–2715.
39. Kee, B.L., M.W. Quong, and C. Murre. 2000. E2A proteins: essen-
tial regulators at multiple stages of B-cell development. Immunol. Rev. 
175:138–149.
40. Hagman, J., C. Belanger, A. Travis, C.W. Turck, and R. Grosschedl. 
1993. Cloning and functional characterization of early B-cell factor, a reg-
ulator of lymphocyte-specifi  c gene expression. Genes Dev. 7:760–773.
41. Lin, H., and R. Grosschedl. 1995. Failure of B-cell diff  erentiation in 
mice lacking the transcription factor EBF. Nature. 376:263–267.
42. Nutt, S.L., B. Heavey, A.G. Rolink, and M. Busslinger. 1999. 
Commitment to the B-lymphoid lineage depends on the transcription 
factor Pax 5. Nature. 401:556–562.
43.  Rolink, A.G., S.L. Nutt, F. Melchers, and M. Busslinger. 1999. Long-
term in vivo reconstitution of T-cell development by Pax5-defi  cient 
B-cell progenitors. Nature. 401:603–606.
44. Schebesta, M., P.L. Pfeff  er, and M. Busslinger. 2002. Control of pre-
BCR signaling by Pax5-dependent activation of the BLNK gene. 
Immunity. 17:473–485.
45.  Souabni, A., C. Cobaleda, M. Schebesta, and M. Busslinger. 2002. Pax5 
promotes B lymphopoiesis and blocks T cell development by repressing 
Notch 1. Immunity. 17:781–793.
46. DeKoter, R.P., and H. Singh. 2000. Regulation of B lymphocyte 
and macrophage development by graded expression of PU. 1. Science. 
288:1439–1441.
47. Ting, C.N., M.C. Olson, K.P. Barton, and J.M. Leiden. 1996. 
Transcription factor GATA-3 is required for development of the T-cell 
lineage. Nature. 384:474–478.
48. Tagoh, H., A. Schebesta, P. Lefevre, N. Wilson, D. Hume, M. 
Busslinger, and C. Bonifer. 2004. Epigenetic silencing of the c-fms lo-
cus during B-lymphopoiesis occurs in discrete steps and is reversible. 
EMBO J. 23:4275–4285.
49. Dahl, R., J.C. Walsh, D. Lancki, P. Laslo, S.R. Iyer, H. Singh, and 
M.C. Simon. 2003. Regulation of macrophage and neutrophil cell fates 
by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating 
  factor. Nat. Immunol. 4:1029–1036.
50.  Martin, C.H., I. Aifantis, M.L. Scimone, U.H. von Andrian, B. Reizis, 
H. von Boehmer, and F. Gounari. 2003. Effi   cient thymic immigra-
tion of B220+ lymphoid-restricted bone marrow cells with T precursor 
  potential. Nat. Immunol. 4:866–873.
51. Allman, D., A. Sambandam, S. Kim, J.P. Miller, A. Pagan, D. Well, 
A. Meraz, and A. Bhandoola. 2003. Thymopoiesis independent of com-
mon lymphoid progenitors. Nat. Immunol. 4:168–174.
52. Born, W., J. White, J. Kappler, and P. Marrack. 1988. Rearrangement 
of IgH genes in normal thymocyte development. J. Immunol. 140:
3228–3232.
53. Singh, H., K.L. Medina, and J.M. Pongubala. 2005. Contingent gene 
regulatory networks and B cell fate specifi  cation. Proc. Natl. Acad. Sci. 
USA. 102:4949–4953.
54.  Maier, H., R. Ostraat, H. Gao, S. Fields, S.A. Shinton, K.L. Medina, T. 
Ikawa, C. Murre, H. Singh, R.R. Hardy, and J. Hagman. 2004. Early 
B cell factor cooperates with Runx1 and mediates epigenetic changes 
associated with mb-1 transcription. Nat. Immunol. 5:1069–1077.
55.  Medina, K.L., J.M. Pongubala, K.L. Reddy, D.W. Lancki, R. Dekoter, 
M. Kieslinger, R. Grosschedl, and H. Singh. 2004. Assembling a 
gene regulatory network for specifi  cation of the B cell fate. Dev. Cell. 
7:607–617.
56. Colucci, F., C. Soudais, E. Rosmaraki, L. Vanes, V.L. Tybulewicz, 
and J.P. Di Santo. 1999. Dissecting NK cell development using a 
novel alymphoid mouse model: investigating the role of the c-abl 
proto-oncogene in murine NK cell diff  erentiation. J. Immunol. 162:
2761–2765.
57. Ikawa, T., H. Kawamoto, S. Fujimoto, and Y. Katsura. 1999. 
Commitment of common T/natural killer (NK) progenitors to unipo-
tent T and NK progenitors in the murine fetal thymus revealed by a 
single progenitor assay. J. Exp. Med. 190:1617–1626.